The KRAS-G12C inhibitor: activity and resistance - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34471232/

Although it has long been deemed "undruggable", with the development of drugs specifically binding the KRAS-G12C mutant protein, clinical trials that directly inhibit oncogenic RAS have recently made promising improvements. In particular, the covalent KRAS-G12C inhibitors sotorasib and adagrasib are ...